Page 150 - Read Online

Kamiya et al. J Cancer Metastasis Treat 2018;4:35 I http://dx.doi.org/10.20517/2394-4722.2017.76 Page 11 of 12

a phase 3 open-label, randomised controlled trial. Lancet 2012;379:315-21.
46. Lee J, Lim do H, Kim S, Park SH, Park JO, Park YS, Lim HY, Choi MG, Sohn TS, Noh JH, Bae JM, Ahn YC, Sohn I, Jung SH, Park CK,
Kim KM, Kang WK. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine
radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 2012;30:268-73.
47. Dikken JL, van Sandick JW, Maurits Swellengrebel HA, Lind PA, Putter H, Jansen EP, Boot H, van Grieken NC, van de Velde CJ, Verheij
M, Cats A. Neoadjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with
resectable gastric cancer (CRITICS). BMC Cancer 2011;11:329.
48. Verheij M, Jansen EPM, Cats A, van Grieken NCT, Aaronson NK, Boot H. A multicenter randomized phase III trial of neo-adjuvant
chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: First results from
the CRITICS study. J Clin Oncol 2016;34 suppl 15:abstr4000.
49. Phase III Randomized Trial of Adjuvant Chemotherapy With S-1 vs S-1/Oxaliplatin ± Radiotherapy for Completely Resected Gastric
Adenocarcinoma: The ARTIST II Trial (ARTIST-II). ClinicalTrials.gov Identifier: NCT01761461.
50. Kumagai K, Rouvelas I, Tsai JA, Mariosa D, Klevebro F, Lindblad M, Ye W, Lundell L, Nilsson M. Meta-analysis of postoperative
morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and
gastro-oesophageal junctional cancers. Br J Surg 2014;101:321-38.
51. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR. Capecitabine and
oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46.
52. Ryu MH, Kang YK. ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer.
Expert Rev Anticancer Ther 2009;9:1745-51.
53. Okines AF, Norman AR, McCloud P, Kang YK, Cunningham D. Meta-analysis of the REAL-2 and ML17032 trials: evaluating
capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced
oesophago-gastric cancer. Ann Oncol 2009;20:1529-34.
54. Al-Batran SE, Homann N, Schmalenberg H, Kopp HG, Haag GM, Luley KB, Schmiegel WH, Folprecht G, Probst S, Prasnikar N, Thuss-
Patience P, Fischbach W, Trojan J, Koenigsmann M, Pauligk C, Goetze TO, Jaeger E, Meiler J, Schuler M, Hofheinz R. Perioperative
chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine
(ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): a multicenter, randomized phase 3
trial. J Clin Oncol 2017;35 suppl:abstr 4004.
55. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Königsrainer
A, Budach W, Wilke H. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally
advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009;27:851-6.
56. Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, Roth JA, Rashid A, Hamilton SR, Wu TT. Posttherapy pathologic
stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 2005;103:1347-55.
57. Leong T, Smithers BM, Haustermans K, Michael M, Gebski V, Miller D, Zalcberg J, Boussioutas A, Findlay M, O’Connell RL, Verghis
J, Willis D, Kron T, Crain M, Murray WK, Lordick F, Swallow C, Darling G, Simes J, Wong R. TOPGEAR: a randomized, phase III trial
of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: interim results from an
international, intergroup trial of the AGITG, TROG, EORTC and CCTG. Ann Surg Oncol 2017;24:2252-8.
58. European Organisation for Research and Treatment of Cancer - EORTC. Integration of trastuzumab, with or without pertuzumab, into
perioperative chemotherapy of HER2- positive stomach cancer: the INNOVATION trial (EORTC-1203-GITCG). Oncol Res Treat
2016;39:153-4; discussion 155.
59. Cunningham D. A randomised phase II/III trial of peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric
adenocarcinoma and a feasibility study evaluating lapatinib in HER-2 positive oesophagogastric adenocarcinomas and (in selected centres)
MRI and PET/CT sub-studies. Available from: http://ichgcp.net/clinical-trials-registry/NCT00450203 [Last accessed on 6 Jul 2018].
60. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and
meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-9.
61. Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, Wenczl M, Goker E, Cisar L, Wang K, Bugat R. Randomized phase III study
comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients
with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008;19:1450-7.
62. Moehler M, Kanzler S, Geissler M, Raedle J, Ebert MP, Daum S, Flieger D, Seufferlein T, Galle PR, Hoehler T. A randomized multicenter
phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction.
Ann Oncol 2010;21:71-7.
63. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Guan Z, Khasanov R, Zheng L, Philco-Salas M, Suarez T,
Santamaria J, Forster G, McCloud PI. Capecitabine/ cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced
gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009;20:666-73.
64. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, Fleig WE. Chemotherapy for advanced gastric cancer. Cochrane
Database Syst Rev 2010;(3):CD004064.
65. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani
JA. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced
gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991-7.
66. Lorenzen S, Pauligk C, Homann N, Schmalenberg H, Jäger E, Al-Batran SE. Feasibility of perioperative chemotherapy with infusional 5-FU,
leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer. Br J
Cancer 2013;108:519-26.
67. Kang JH, Lee SI, Lim do H, Park KW, Oh SY, Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, Lee J, Park JO, Park YS, Lim HY,
Kang WK, Park SH. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best